RET signaling is required for survival and normal function of nonpeptidergic nociceptors.
Small unmyelinated sensory neurons classified as nociceptors are divided into two subpopulations based on phenotypic differences, including expression of neurotrophic factor receptors. Approximately half of unmyelinated nociceptors express the NGF receptor TrkA, and half express the GDNF family ligand (GFL) receptor Ret. The function of NGF/TrkA signaling in the TrkA population of nociceptors has been extensively studied, and NGF/TrkA signaling is a well established mediator of pain. The GFLs are analgesic in models of neuropathic pain emphasizing the importance of understanding the physiological function of GFL/Ret signaling in nociceptors. However, perinatal lethality of Ret-null mice has precluded the study of the physiological role of GFL/Ret signaling in the survival, maintenance, and function of nociceptors in viable mice. We deleted Ret exclusively in nociceptors by crossing nociceptor-specific Na(v)1.8 Cre and Ret conditional mice to produce Ret-Na(v)1.8 conditional knock-out (CKO) mice. Loss of Ret exclusively in nociceptors results in a reduction in nociceptor number and size, indicating that Ret signaling is important for the survival and trophic support of these cells. Ret-Na(v)1.8 CKO mice exhibit reduced epidermal innervation but normal central projections. In addition, Ret-Na(v)1.8 CKO mice have increased sensitivity to cold and increased formalin-induced pain, demonstrating that Ret signaling modulates the function of nociceptors in vivo. Enhanced inflammation-induced pain may be mediated by decreased prostatic acid phosphatase (PAP), as PAP levels are markedly reduced in Ret-Na(v)1.8 CKO mice. The results of this study identify the physiological role of endogenous Ret signaling in the survival and function of nociceptors.
Golden
Judith P
JP
Washington University Pain Center, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. jgolden@wustl.edu
Hoshi
Masato
M
Nassar
Mohammed A
MA
Enomoto
Hideki
H
Wood
John N
JN
Milbrandt
Jeffrey
J
Gereau
Robert W
RW
Johnson
Eugene M
EM
Jain
Sanjay
S
D000818:Animals; D002470:Cell Survival / Q000235:genetics / Q000502:physiology; D005260:Female; D005557:Formaldehyde / Q000008:administration & dosage; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D062559:NAV1.8 Voltage-Gated Sodium Channel; D009619:Nociceptors / Q000166:cytology / Q000502:physiology*; D010147:Pain Measurement / Q000379:methods; D051096:Proto-Oncogene Proteins c-ret / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology*; D015222:Sodium Channels / Q000172:deficiency / Q000235:genetics
D062559:NAV1.8 Voltage-Gated Sodium Channel; C568317:SCN10A protein, human; C568318:Scn10a protein, mouse; D015222:Sodium Channels; D005557:Formaldehyde; D051096:Proto-Oncogene Proteins c-ret